Evotec AG (NASDAQ:EVO) Given Average Recommendation of “Hold” by Brokerages

Shares of Evotec AG (NASDAQ:EVO) have been assigned a consensus recommendation of “Hold” from the five research firms that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $7.00.

EVO has been the subject of several recent analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Evotec in a research report on Monday, December 29th. Berenberg Bank began coverage on shares of Evotec in a research report on Tuesday, February 3rd. They issued a “buy” rating for the company. Finally, Wall Street Zen upgraded shares of Evotec from a “sell” rating to a “hold” rating in a research note on Saturday, January 10th.

Institutional Investors Weigh In On Evotec

A number of institutional investors and hedge funds have recently added to or reduced their stakes in EVO. Marshall Wace LLP acquired a new stake in shares of Evotec in the fourth quarter valued at approximately $40,000. Valeo Financial Advisors LLC acquired a new stake in Evotec during the 2nd quarter worth $43,000. BNP Paribas Financial Markets grew its position in Evotec by 62.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 12,000 shares of the company’s stock worth $50,000 after purchasing an additional 4,600 shares during the last quarter. Bank of America Corp DE grew its position in Evotec by 262.5% during the 4th quarter. Bank of America Corp DE now owns 12,828 shares of the company’s stock worth $53,000 after purchasing an additional 9,289 shares during the last quarter. Finally, Thrivent Financial for Lutherans acquired a new position in Evotec in the third quarter valued at $53,000. Hedge funds and other institutional investors own 5.81% of the company’s stock.

Evotec Stock Performance

Shares of NASDAQ EVO opened at $3.27 on Friday. The stock’s 50-day simple moving average is $3.48 and its 200-day simple moving average is $3.48. Evotec has a fifty-two week low of $2.84 and a fifty-two week high of $4.80. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.12 and a quick ratio of 2.03.

Evotec Company Profile

Evotec SE (NASDAQ:EVO) is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.

Evotec’s service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.